Free Trial
NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

$7.54
-0.06 (-0.79%)
(As of 03:33 PM ET)
Today's Range
$7.24
$7.86
50-Day Range
$7.60
$16.50
52-Week Range
$7.24
$29.70
Volume
209,285 shs
Average Volume
293,568 shs
Market Capitalization
$156.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

Adverum Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
289.3% Upside
$29.00 Price Target
Short Interest
Healthy
5.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.34mentions of Adverum Biotechnologies in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.42) to ($5.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.17 out of 5 stars

Medical Sector

260th out of 931 stocks

Biological Products, Except Diagnostic Industry

38th out of 154 stocks

ADVM stock logo

About Adverum Biotechnologies Stock (NASDAQ:ADVM)

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

ADVM Stock Price History

ADVM Stock News Headlines

Adverum Biotechnologies Inc
Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen
ADVM Adverum Biotechnologies, Inc.
ADVM Apr 2024 5.000 call
Stocks on the Launchpad: The Next 3 Market Sensations
See More Headlines
Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
5/28/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADVM
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.00
High Stock Price Target
$60.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+281.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-117,170,000.00
Pretax Margin
-3,284.53%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$8.26 per share

Miscellaneous

Free Float
19,885,000
Market Cap
$157.78 million
Optionable
Optionable
Beta
0.89
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Laurent FischerDr. Laurent Fischer (Age 60)
    President, CEO & Director
    Comp: $1.02M
  • Ms. Linda M. Rubinstein M.A. (Age 57)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $940.99k
  • Mr. Kishor Peter Soparkar J.D. (Age 53)
    Chief Operating Officer
    Comp: $674.98k
  • Dr. Setareh Seyedkazemi Pharm.D. (Age 50)
    Chief Development Officer
    Comp: $656.84k
  • Dr. R. Andrew Ramelmeier Ph.D. (Age 62)
    Chief Technology Officer
  • Dr. Romuald Corbau Ph.D. (Age 55)
    Chief Scientific Officer
  • Mr. John W. Rakow J.D. (Age 67)
    Senior VP & General Counsel
    Comp: $954.24k
  • Ms. Dena House
    Chief People Officer
  • Ms. Carla Fiankan
    Senior Vice President of Regulatory Affairs
  • Mr. Michael Steel
    Senior Vice President of Quality

ADVM Stock Analysis - Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADVM shares.
View ADVM analyst ratings
or view top-rated stocks.

What is Adverum Biotechnologies' stock price target for 2024?

4 brokers have issued 1-year price objectives for Adverum Biotechnologies' stock. Their ADVM share price targets range from $4.00 to $60.00. On average, they predict the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 289.3% from the stock's current price.
View analysts price targets for ADVM
or view top-rated stocks among Wall Street analysts.

How have ADVM shares performed in 2024?

Adverum Biotechnologies' stock was trading at $7.5280 at the beginning of the year. Since then, ADVM shares have decreased by 1.0% and is now trading at $7.45.
View the best growth stocks for 2024 here
.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a drop in short interest in May. As of May 15th, there was short interest totaling 762,200 shares, a drop of 36.5% from the April 30th total of 1,200,000 shares. Based on an average daily volume of 308,400 shares, the days-to-cover ratio is currently 2.5 days. Currently, 5.9% of the shares of the company are short sold.
View Adverum Biotechnologies' Short Interest
.

When is Adverum Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our ADVM earnings forecast
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its earnings results on Monday, March, 18th. The biotechnology company reported ($2.30) earnings per share for the quarter, beating the consensus estimate of ($2.80) by $0.50.

When did Adverum Biotechnologies' stock split?

Adverum Biotechnologies's stock reverse split before market open on Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Vivo Capital LLC (7.23%), Vanguard Group Inc. (4.37%), BML Capital Management LLC (4.01%), Versant Venture Management LLC (2.44%), Avoro Capital Advisors LLC (2.01%) and Assenagon Asset Management S.A. (1.73%). Insiders that own company stock include Brigit Riley, Dawn Svoronos, James Paul Scopa, Julie Clark, Laurent Fischer, Peter Soparkar, Richard Beckman, Rupert D'souza and Setareh Seyedkazemi.
View institutional ownership trends
.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADVM) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners